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screenAbstract Several 9-chloro-11H-indeno[1,2-c]quinolin-11-one derivatives have been designed which
is replacing side chains with different groups containing oxygen, nitrogen or sulfur atoms. Substi-
tution of C-6 on the starting structure, 6,9-dichloro-11H-indeno[1,2-c]quinolin-11-one, using appo-
site nucleophilic group with a suitable base or acid could be obtained 28 novel tetracyclic
azafluorenone derivatives. The cytotoxic activity of these analogues was examined in cancer cell
lines by MTT assay and compounds 4, 5, 13, and 26 were selected to evaluate in topoisomerase I
drug screening assay, respectively. At the same time, 17 compounds were selected for NCI-60 anti-
cancer drug screen to prevent the narrower concept of an in vitro screening model. Its worth to find, Taipei
e I inhi-
2 T.-C. Chen et al.
Please cite this article in press as: Chen, T.-C
bitory properties as potential anticancer agethat 9-chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c]quinolin-11-one (12) showed greater cytotoxicity
than another azafluorenone derivatives with an average GI50 of 10.498 lM over 60 cell lines. We
also found that another analogue, 9-chloro-6-(2-methylpiperazin-1-yl)-11H-indeno[1,2-c]quinolin-
11-one (13), exhibited preferential growth inhibition effect toward cancer cell lines and showed a
significant inhibitory effect on topoisomerase I.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Camptothecin (CPT) is a cytotoxic quinoline alkaloid, as well as TAS-
103 is a quinoline derivative which has been reported to be potent
topoisomerase (topo) I and/or topo II poison (Aoyagi et al., 2000;
Fujimoto, 2007; Yoshida et al., 2008; Shah et al., 2010). Two clinically
anticancer drugs, irinotecan and topotecan, are derivatives of the CPT
family that are used in colorectal cancer, either as single agents or in
combination with radiotherapy and/or other chemotherapy drugs
(Kehrer et al., 2001; Alagoz et al., 2012). Despite clinical success, they
are the only Topo I-targeted anticancer drugs which still have several
problems with CPT-derived anticancer agents (Teicher, 2008). Ongo-
ing research aims to the lactone and A-D planar ring in CPT and its
analogues and derivatives which suffer from major limitation and
application drawback of non-mechanism related toxicity and poor
solubility profile (Ulukan and Swaan, 2002; Kiselev et al., 2012;
Perzyna et al., 2003). Because the direct target of above small mole-
cules remained unclear, we tried structural hybridization of some
preclinical and clinical anticancer drugs to design tetracyclic
azafluorenone-derived small molecules as potential anticancer drugs
(Fig. 1).
The anthracycline antibiotics (e.g. doxorubicin, daunorubicin,
mitoxantrone and ametantrone) have been shown to provide signifi-
cant antiproliferative (or cytostatic) properties (Chen et al., 2013,
2015) and inhibit topoisomerase II (Suzuki et al., 1995) as well as inter-
calate into the minor groove of double-strand DNA base pairs via the
core planar pharmacophore group (Wang et al., 1994). In addition,
DMMA (6,8-dihydroxy-7-methoxy-1-methyl-3-azafluorenone), an
active compound of the azafluorenone, was isolated from Polyalthia
cerasoides in 2010 (Pumsalid et al., 2010) which exhibits cytotoxic to
various cancer cell lines (Banjerdpongchai et al., 2013). Moreover,
recent studies illustrated related indenoquinoline skeleton incorporate
ring system and various substituents had been found as potential dual
topo I/II inhibitors and anticancer candidates (Tseng et al., 2013, 2010,
2009, 2008). There are also several studies have found that
azafluorenone-derived compounds had potent anticancer
(Coothankandaswamy et al., 2010; McLaughlin, 2008; Pan et al.,
2011), cytotoxic (Pumsalid et al., 2010), antimicrobial (Koyama
et al., 2005; Addla et al., 2012), antitubercular (Yempala et al.,
2012), anti-inflammatory (Chuang et al., 2008; Rojano et al., 2007)
and antiprotozoal activities (Waechter et al., 1999).
Based on above considerations, azafluorenones can be considered
as an attractive scaffold for the development of anticancer reagents.
In the past, several studies had found that DNA top IB can regulate
DNA topological structures by sequential breakage and is involved
in DNA transcription, replication, and recombination (Shen et al.,
2010; Stewart et al., 1998). Toward supporting the aforementioned
hypothesis, we recently disclosed evidence as well as an in-depth con-
tinuous investigation toward synthesis of fluorenone analogs (Lee
et al., 2013) led to discovery of azafluorenone-derived scaffold small
molecules for the polypharmacology. With this motivation, we herein
also describe efficient synthetic procedures for the preparation of a ser-
ies of non-nucleoside fused tetracyclic compounds comprising benzene
moiety and an azafluorenone backbone. We attempted to identify
additional potent enzyme inhibitors and work toward some. et al., Design, synthesis and biologica
nts. Arabian Journal of Chemistry (201azafluorenone-derived structural modifications in order to develop
some potential anticancer structures leads which could be compared
to parent molecules in cancer chemotherapy.2. Chemistry
2.1. Materials and instruments
The Pfitzinger synthetic reaction of isatin and 4-
chlorophenylacetic acid was stirred at 200 C with sodium
acetate (NaOAc) as a basic catalyst for 3 h to obtain com-
pound 1 (52%) as a key intermediate. An isatin was reacted
with NaOAc as base by the amide bond hydrolysis to obtain
2-(2-aminophenyl)-2-oxoacetic acid. A reactant with a ketone
group reacted with the aniline to give the imine and the enam-
ine. The enamine cyclized and dehydrated to give the desired
quinoline-4-carboxylic acids (1). Treatment of 1 with phospho-
ryl trichloride (POCl3) afforded 6,9-dichloro-11H-indeno[1,2-
c]quinolin-11-one (2). A series of 6-substituted 9-chloro-11H-
indeno[1,2-c]quinolin-11-one homologues can be synthesized
and the preparation involved various synthetic routes with
approximate yields (overall 17–95%) in all steps: (i) reaction
of isatin with 4-chlorophenylacetic acid and NaOAc; (ii) reac-
tion of 1 with POCl3; and (iii) reaction of compound 2 with a
series of apposite primary or secondary amines, 2-
mercaptoethanol, conc. hydrochloride (HCl), or sodium
methoxide yielded the corresponding side chain compounds
3–29, respectively (Scheme 1). The quantity of the isolated
products was dependent on substrate and reaction condition.
All the crude mixtures were purified through tedious recrystal-
lization from ethyl acetate/n-hexane and/or ethanol. The
molecular weight of all synthetic compounds was determined
by HRMS. The protons and carbons from tetracyclic azafluo-
renone structures were also obvious from the 1H NMR and
13C NMR spectra.
2.2. Synthesis of target compounds 1–29
The synthetic methods and physical data of compounds 1–29
were described and all compounds were tested and compared
for their growth inhibition, cytotoxicity and topoisomerase
activities. In this study, we synthesized and dedicated on the
role of our systematic, tetracyclic, and heterocyclic pharma-
cophore by introducing a series of side chains linked to the
9-chloro-11H-indeno[1,2-c]quinolin-11-one moiety.
All reactions were monitored through a TLC (silica gel 60
F254) plate with a 254-nm UV lamp.
1H NMR and 13C
NMR were measured on Varian GEMINI-300 (300 MHz) or
Agilent 400 MR DD2 (400 MHz); d values are in ppm relativel evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
6), http://dx.doi.org/10.1016/j.arabjc.2016.06.014
Figure 1 Structural hybridization design of tetracyclic quinoline derivatives.
Design, synthesis and biological evaluation of tetracyclic azafluorenone derivatives 3to TMS (tetramethylsilane) as an internal standard. Multiplic-
ities are recorded as s (singlet), d (doublet), t (triplet), q (quar-
tet), quin (quintuplet), dd (doublet of doublets), dt (triplet of
doublets), td (doublet of triplets), m (multiplet), and br (broad-
ened). Mass spectra: High resolution electrospray ionization
(HRESI): Finnigan MAT 95S (Instrumentation Center,
National Taiwan University, Taipei, Taiwan) and High resolu-
tion electron impact ionization (HREI): Finnigan MATMAT-
95XL (Instrumentation Center, National Tsing Hua Univer-
sity, Hsinchu, Taiwan). Melting points of synthetic com-
pounds were determined with a Bu¨chi B-545 melting point
apparatus. Typical experiments illustrating the synthetic pro-
cedures for the preparation of the tetracyclic small molecules
are described below. These compounds were synthesized, start-
ing from isatin and 4-chloro-phenylacetic acid. All the reagents
and solvents required for synthesis were purchased from eitherPlease cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (201Merck Chemical Company or Sigma–Aldrich Chemical Com-
pany without further purification.
2.2.1. Synthetic procedure i: preparation of compound 1
A mixture of isatin (3.14 g, 21 mmol), 4-chloro-phenylacetic
acid (3.41 g, 20 mmol), and sodium acetate (1.00 g) was heated
at 200 C for 2 h (TLC monitoring). After cooling, 100 mL
acetic acid was added to the mixture. The precipitate was fil-
trated and washed with acetic acid and n-hexane, and then col-
lected the obtained orange compound.
2.2.2. Synthetic procedure ii: preparation of compound 2
A suspension of compound 1 (3.03 g, 10.1 mmol) and POCl3
(20 mL) was stirred and heated at 150 C for 48 h. After cool-
ing, the mixture was poured into ice-water (300 mL) at 0 C
cautiously. The resulting precipitate that separated was col-l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
6), http://dx.doi.org/10.1016/j.arabjc.2016.06.014
Scheme 1 Overall synthetic routes of the tetracyclic azafluorenone derivatives. Reagents and conditions: (i) 1: NaOAc, 200 C, 2 h; (ii) 2:
POCl3, 150 C, reflux, 48 h; (iii) 3–26: appropriate amines, DMF, pyridine, miniclave, 150 C, 2 h; 27: mercaptoethanol, K2CO3; 28:
DMF, conc. HCl, reflux, 24 h; 29: NaOMe, MeOH, reflux, 16 h.
4 T.-C. Chen et al.lected by filtration. The filtered cake was suspended in 10%
NaHCO3 solution (300 mL) with vigorous stirring for 1 h.
The resulting precipitate was collected and washed with
H2O. The crude was recrystallized from dichloromethane to
give an orange product.
2.2.3. General procedure iii: preparation of compounds 3–26
Compound 2, primary or secondary amine (10 mmol) and N,
N-diisopropylethylamine (DIPEA) (2 mmol) were dissolved
in miniclave containing DMF (10 mL) and stirred at 150 C
for 4 h. The reaction was poured into ice-water (100 mL).
The resulting precipitate was collected by filtration and puri-
fied by crystallization from ethanol to afford desired
compound.Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (2012.2.4. Synthetic procedure iv: preparation of compound 27
Compound 2, 2-mercaptoethanol (10 mmol) and N,N-
diisopropylethylamine (DIPEA) (2 mmol) were dissolved in
miniclave containing DMF (10 mL) and stirred at room
150 C for 4 h. The reaction was poured into ice-water
(100 mL). The resulting precipitate was collected by filtration
and purified by crystallization from ethanol to afford desired
compounds.
2.2.5. Synthetic procedure v: preparation of compound 28
A mixture of compound 2, conc. HCl (2 mL) and DMF
(10 mL) was refluxed at 120 C. After 4 h, the conc. HCl was
added into the reaction again (TLC monitored). The mixturel evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
6), http://dx.doi.org/10.1016/j.arabjc.2016.06.014
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H2O (20 mL), and filtered. The crude solid was washed with
EtOH to give 28 as a red solid.
2.2.6. Synthetic procedure vi: preparation of compound 29
A methanol solution (20 mL) containing sodium methoxide
(1.08 g, 20 mmol) was slowly added into the suspension of
compound 2 in MeOH (10 mL) for 10 min. The reaction was
refluxed at 100 C for 16 h (TLC monitored). After cooled,
the solvent was removed by rotary evaporator vacuum, fil-
trated and washed with ethanol and n-hexane to collect an
orange solid.
2.3. Physical data
2.3.1. 3-(4-Chlorophenyl)-2-hydroxyquinoline-4-carboxylic acid
(1)
The pure compound was obtained as an orange solid (yield
80%). Mp 310–311 C (EtOH). FT-IR (KBr; m cm1): 3234
(NH), 1637 (CO). 1H NMR (300 MHz, CDCl3): d (ppm)
6.60 (s, 1H, AOH), 6.91 (td, J= 7.2 Hz, 0.6 Hz, 1H, ArAH),
7.12 (d, J= 8.4 Hz, 1H, ArAH), 7.51 (d, J= 8.7 Hz, 2H,
ArAH), 7.53–7.59 (m, 2H, ArAH), 7.74 (d, J= 8.7 Hz,
2H, ArAH), 9.83 (s, 1H, ACOOH). 13C NMR (75 MHz,
CDCl3): d (ppm) 117.12, 120.66, 121.83, 122.20, 126.31,
128.86, 129.15, 132.67, 134.22, 135.21, 136.23, 139.59,
182.29 (CO). HRMS (ESI) m/z calcd for C16H10NO3Cl
+
[M]+ 299.0349, found [M+H]+: 300.0424, [MH]:
298.0238.
2.3.2. 6,9-Dichloro-11H-indeno[1,2-c]quinolin-11-one (2)
Product 2 was cyclized from compound 1 using POCl3 at
150 C for 48 h. The red solid material was isolated in 30%
yield. (Rf = 0.70 at CH2Cl2). Mp 241–243 C. FT-IR (KBr;
m cm1): 1719 (C‚O). 1H NMR (300 MHz, CDCl3) d
(ppm): 7.52 (dd, J= 8.25, 1.8 Hz, 1H, ArAH), 7.62–7.68 (m,
2H, ArAH), 7.70–7.76 (m, 1H, ArAH), 7.97–8.01 (dt,
J= 7.5, 0.6 Hz, 1H, ArAH), 8.10 (d, J= 7.8 Hz, 1H, ArAH),
8.77–8.80 (m, 1H, ArAH). 13C NMR (75 MHz, CDCl3) d
(ppm): 122.97, 124.59, 125.30, 125.69, 129.13, 130.32, 131.70,
135.06, 135.14, 136.19, 136.74, 136.80, 140.15, 145.25, 150.48,
192.80 (CO). HRMS (ESI) m/z calcd for C16H7NOCl2
+,
[M]+: 298.9905, found [M+H]+: 299.9965 (100), 301.9947
(65), 303.9917 (10).
2.3.3. 9-Chloro-6-(methylamino)-11H-indeno[1,2-c]quinolin-
11-one (3)
Product 3 was prepared from compound 2 and methylamine.
The red solid material was isolated in 75% yield (Rf = 0.51 at
CH2Cl2: n-hexane = 2:1). Mp 189–191 C (EtOH). FT-IR
(KBr; m cm1): 1716 (C‚O). 1H NMR (300 MHz, CDCl3):
d (ppm) 3.01 (s, 3H, NACH3), 7.41–7.47 (m, 2H, ArAH),
7.57–7.62 (m, 3H, ArAH), 7.84 (d, J= 8.4 Hz, 1H, ArAH),
8.68 (d, J= 8.1 Hz, 1H, ArAH). 13C NMR (75 MHz,
CDCl3): d (ppm) 42.22, 120.81, 124.29, 124.93, 124.99,
127.02, 128.13, 130.44, 131.60, 134.33, 135.16, 135.24,
136.59, 141.85, 149.69, 158.14, 194.48 (CO). HRMS (ESI)
m/z calcd for C17H11N2OCl
+ [M]+: 294.0560, found
[M+H]+: 295.0634.Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (2012.3.4. 9-Chloro-6-(dimethylamino)-11H-indeno[1,2-c]quinolin-
11-one (4)
Product 4 was prepared from compound 2 and dimethylamine.
The red solid material was isolated in 74.5% yield (Rf = 0.51
at CH2Cl2: n-hexane = 1:1). Mp 193–195 C (EtOH). FT-IR
(KBr; m cm1): 3407 (NH), 1718 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 3.04 (s, 6H, ANA(CH3)2), 7.41–
7.48 (m, 2H, ArAH), 7.57–7.63 (m, 3H, ArAH), 7.86 (d,
J= 8.7 Hz, 1H, ArAH), 8.68–8.71 (m, 1H, ArAH). 13C
NMR (75 MHz, CDCl3): d (ppm) 42.19, 120.80, 124.27,
124.91, 124.96, 126.99, 128.13, 130.40, 131.57, 134.30, 135.14,
135.22, 136.54, 141.84, 149.70, 158.13, 194.45 (CO). HRMS
(EI) m/z calcd for C18H13N2OCl
+ [M]+: 308.0716, found
308.0708.
2.3.5. 6-(2-(Diethylamino)ethylamino)-9-chloro-11H-indeno
[1,2-c]quinolin-11-one (5)
Product 5 was prepared from compound 2 and N1,N1-
diethylethane-1,2-diamine. The red solid material was isolated
in 17.5% yield (Rf = 0.46 at CH2Cl2: n-hexane = 2:1). Mp
160–161 C (EtOH). FT-IR (KBr; m cm1): 3317 (NH), 1712
(C‚O). 1H NMR (300 MHz, CDCl3): d (ppm) 1.11 (t,
J= 7.2 Hz, 6H, ACH3), 2.66 (q, J= 7.1 Hz, 4H, ANCH2A),
2.84 (t, J= 5.7 Hz, 2H, ACH2NA), 3.71–3.73 (m, 2H,
ANHCH2A), 6.14 (br, 1H, NH), 7.28–7.33 (m, 1H, ArAH),
7.41–7.55 (m, 3H, ArAH), 7.60 (d, J= 1.5 Hz, 1H, ArAH),
7.70 (d, J= 8.7 Hz, 1H, ArAH), 8.60 (m, J= 8.1 Hz, 1H,
ArAH). 13C NMR (75 MHz, CDCl3): d (ppm) 12.23, 38.81,
46.92, 51.64, 119.00, 122.48, 124.42, 124.95, 125.40, 126.94,
127.86, 130.53, 134.07, 134.90, 135.08, 135.45, 141.24, 150.68,
152.96, 194.65 (CO). HRMS (ESI) m/z calcd for C22H22N3-
OCl+ [M]+: 379.1451, found[M+H]+: 380.1510.
2.3.6. 9-Chloro-6-(pyrrolidin-1-yl)-11H-indeno[1,2-c]quinolin-
11-one (6)
Product 6 was prepared from compound 2 and pyrrolidine.
The red solid material was isolated in 43.6% yield
(Rf = 0.51 at CH2Cl2: n-hexane = 2:1). Mp 149–150 C
(EtOH). FT-IR (KBr; m cm1): 1718 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 1.98 (quin, J= 3.6 Hz, 4H,
pyrrolidine-H), 3.56 (t, J= 6.6 Hz, 4H, pyrrolidine-H), 7.33–
7.42 (m, 3H, ArAH), 7.54 (td, J= 7.5, 1.5 Hz, 2H, ArAH),
7.76 (d, J= 8.4 Hz, 1H, ArAH), 8.63 (dd, J= 8.4, 0.9 Hz,
1H, ArAH). 13C NMR (75 MHz, CDCl3): d (ppm) 25.07,
50.37, 120.39, 124.25, 124.80, 124.96, 126.29, 127.78, 130.33,
130.40, 134.10, 134.83, 135.27, 136.46, 142.50, 149.78, 155.73,
194.65 (CO). HRMS (ESI) m/z calcd for C20H15N2OCl
+
[M]+: 334.0873, found [M+H]+: 335.0952.
2.3.7. 9-Chloro-6-(piperidin-1-yl)-11H-indeno[1,2-c]quinolin-
11-one (7)
Product 7 was prepared from compound 2 and piperidine. The
red solid material was isolated in 43% yield (Rf = 0.63 at
CH2Cl2: n-hexane = 2:1). Mp 191–192 C (EtOH). FT-IR
(KBr; m cm1): 1717 (C‚O). 1H NMR (300 MHz, CDCl3): d
(ppm) 1.71 (br, 2H, piperidine-H), 1.83–1.86 (m, 4H,
piperidine-H), 3.33 (br, 4H, piperidine-H), 7.43–7.48 (m, 2H,
ArAH), 7.58–7.66 (m, 3H, ArAH), 7.90 (d, J= 8.1 Hz, 1H,
ArAH), 8.70 (d, J= 8.7 Hz, 1H, ArAH). 13C NMRl evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
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6 T.-C. Chen et al.(75 MHz, CDCl3): d (ppm) 224.37, 26.01, 51.30, 120.81,
124.22, 124.41, 124.83, 127.09, 128.29, 130.24, 131.88, 134.24,
135.01, 135.17, 136.35, 142.05, 149.79, 158.35, 194.38 (CO).
HRMS (ESI) m/z calcd for C21H17N2OCl
+ [M]+: 348.1029,
found [M+H]+: 349.1106.
2.3.8. 9-Chloro-6-(4-methylpiperidin-1-yl)-11H-indeno[1,2-c]
quinolin-11-one (8)
Product 8 was prepared from compound 2 and 4-
methylpiperidine. The brown solid material was isolated in
25.4% yield (Rf = 0.61 at CH2Cl2: n-hexane = 2:1). Mp
190–192 C (EtOH). FT-IR (KBr; m cm1): 1718 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 1.07 (d, J= 6 Hz, 3H,
ACH3), 1.46–1.60 (m, 3H, ACH2A, ACHA), 1.84–1.87 (m,
2H, ACH2A), 2.96 (t, J= 11.6 Hz, 2H, ANCH2A), 3.67–
3.71 (m, 2H, ANCH2A), 7.44–7.46 (m, 2H, ArAH), 7.58 (m,
3H, ArAH), 7.82–7.85 (m, 1H, ArAH), 8.66–8.69 (m, 1H,
ArAH). 13C NMR (75 MHz, CDCl3): d (ppm) 22.07, 30.87,
34.43, 50.69, 120.88, 124.27, 124.46, 124.91, 127.15, 128.31,
130.32, 131.98, 134.33, 135.07, 135.23, 136.44, 142.13, 149.83,
158.25, 194.52 (CO). HRMS (ESI) m/z calcd for C22H19N2-
OCl+ [M]+: 362.1186, found [M+H]+: 363.1260.
2.3.9. 6-(Azepan-1-yl)-9-chloro-11H-indeno[1,2-c]quinolin-11-
one (9)
Product 9was prepared from compound 2 and azepane. The red
solid material was isolated in 36% yield (Rf = 0.69 at CH2Cl2:
n-hexane = 2:1). Mp 146–147 C (EtOH). FT-IR (KBr; m
cm1): 1712 (C‚O). 1H NMR (300 MHz, CDCl3): d (ppm)
1.72–1.75 (m, 4H, ACH2A), 1.86 (br, 4H, ACH2A), 3.64 (t,
J= 5.6 Hz, 4H, ANCH2A), 7.40–7.46 (m, 2H, ArAH), 7.54–
7.60 (m, 3H, ArAH), 7.78–7.80 (m, 1H, ArAH), 8.68 (dd,
J= 8.4, 0.6 Hz, 1H, ArAH). 13C NMR (75 MHz, CDCl3): d
(ppm) 27.96, 28.40, 52.91, 120.48, 124.24, 124.76, 124.89,
126.60, 127.98, 130.30, 131.09, 134.13, 134.97, 135.15, 136.84,
142.54, 149.74, 157.83, 194.62 (CO). HRMS (ESI) m/z calcd
for C22H19N2OCl
+ [M]+: 362.1186, found [M+H]+: 363.2000.
2.3.10. 9-Chloro-6-morpholino-11H-indeno[1,2-c]quinolin-11-
one (10)
Product 10 was prepared from compound 2 and morpholine.
The red solid material was isolated in 47% yield (Rf = 0.54
at CH2Cl2: n-hexane = 2:1). Mp 207–208 C (EtOH). FT-IR
(KBr; m cm1): 1712 (C‚O). 1H NMR (300 MHz, CDCl3): d
(ppm) 3.41 (t, J= 4.5 Hz, 4H, ACH2A), 3.98 (t, J= 4.5 Hz,
4H, ACH2A), 7.48 (td, J= 8.1, 2.1 Hz, 2H, ArAH), 7.59–
7.65 (m, 3H, ArAH), 7.87 (d, J= 8.7 Hz, 1H, ArAH), 8.69–
8.72 (dt, J= 8.1, 0.9 Hz, 1H, ArAH). 13C NMR (75 MHz,
CDCl3): d (ppm) 50.56, 66.98, 121.18, 124.35, 124.43, 125.23,
127.65, 128.51, 130.59, 131.46, 134.42, 135.21, 135.55, 136.80,
141.66, 149.81, 157.31, 194.14 (CO). HRMS (ESI) m/z calcd
for C20H15N2O2Cl
+ [M]+: 350.0822, found [M+H]+:
351.0898.
2.3.11. 9-Chloro-6-thiomorpholino-11H-indeno[1,2-c]quinolin-
11-one (11)
Product 11 was prepared from compound 2 and thiomorpho-
line. The orange solid material was isolated in 74% yield
(Rf = 0.33 at CH2Cl2: n-hexane = 2:1). Mp 228–230 CPlease cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (201(EtOH). FT-IR (KBr; m cm1): 1711 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 2.91 (t, J= 5.1 Hz, 4H,ACH2A),
2.69–2.73 (br, 4H, ACH2A), 7.45–7.50 (td, J= 7.8, 1.8 Hz,
2H, ArAH), 7.57–7.64 (m, 3H, ArAH), 7.85 (d, J= 9.0 Hz,
1H, ArAH), 8.68–8.71 (dd, J= 8.25, 1.2 Hz, 1H, ArAH).
13C NMR (75 MHz, CDCl3): d (ppm) 27.38, 52.36, 121.07,
124.29, 125.19, 127.66, 128.48, 129.44, 130.57, 131.59, 134.40,
135.10, 135.54, 136.87, 141.70, 149.70, 157.66, 194.17 (CO).
HRMS (ESI) m/z calcd for C20H15N2OSCl
+ [M]+:
366.0594, found [M+H]+: 367.0664.
2.3.12. 9-Chloro-6-(piperazin-1-yl)-11H-indeno[1,2-c]quinolin-
11-one (12)
Product 12 was prepared from compound 2 and piperazine.
The red solid material was isolated in 48% yield (Rf = 0.43
at CH2Cl2: n-hexane = 2:1). Mp 180–181 C. FT-IR (KBr; m
cm1): 3341 (NH), 1718 (C‚O). 1H NMR (300 MHz, CDCl3):
d (ppm) 3.16 (t, J= 4.8 Hz, 4H, ACH2A), 3.36 (br, 4H,
ACH2A), 7.46–7.49 (m, 2H, ArAH), 7.62–7.66 (m, 3H,
ArAH), 7.87 (d, J= 8.7 Hz, 1H, ArAH), 8.71 (d,
J= 8.7 Hz, 1H, ArAH). 13C NMR (75 MHz, CDCl3): d
(ppm) 46.17, 51.51, 121.05, 124.31, 124.54, 125.11, 127.45,
128.46, 130.48, 131.69, 134.39, 135.16, 135.40, 136.68, 141.88,
149.84, 157.83, 194.37 (CO). HRMS (ESI) m/z calcd for C20-
H16N3OCl
+ [M]+: 349.0982, found [M+H]+: 350.1063.
2.3.13. 9-Chloro-6-(2-methylpiperazin-1-yl)-11H-indeno[1,2-c]
quinolin-11-one (13)
Product 13 was prepared from compound 2 and 3-
methylpiperazine. The red solid material was isolated in 18%
yield (Rf = 0.49 at CH2Cl2: n-hexane = 4:1). Mp 199–200 C
(EtOH). FT-IR (KBr; m cm1): 3222 (NH), 1719 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 1.17 (d, J= 6.3 Hz, 3H,
ACH3), 2.70 (t, 1H, ACH2A), 3.03–3.07 (m, 1H, ANCHA),
3.15–3.19 (m, 3H, ACH2A, ACH2NHA), 3.60–3.65 (d,
J= 12.6 Hz, 2H, ANHCH2A), 7.44–7.48 (m, 2H, ArAH),
7.58–7.62 (m, 3H, ArAH), 7.86 (d, J= 8.4 Hz, 1H, ArAH),
8.69 (d, J= 7.8 Hz, 1H, ArAH). 13C NMR (75 MHz, CDCl3):
d (ppm) 19.96, 45.98, 50.63, 50.75, 57.67, 120.98, 124.29,
124.47, 125.09, 127.39, 128.41, 130.47, 131.63, 134.37, 135.15,
135.36, 136.65, 141.89, 149.82, 157.56, 194.36 (CO). HRMS
(ESI) m/z calcd for C21H18N3OCl
+ [M]+: 363.1138, found
[M+H]+: 364.1201.
2.3.14. 9-Chloro-6-(4-methylpiperazin-1-yl)-11H-indeno[1,2-c]
quinolin-11-one (14)
Product 14 was prepared from compound 2 and 1-
methylpiperazine. The red solid material was isolated in 51%
yield (Rf = 0.4 at CH2Cl2: n-hexane = 2:1). Mp 205–207 C
(EtOH). FT-IR (KBr; m cm1): 3462 (NH), 1720 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 2.42 (s, 3H, N-CH3), 2.70
(br, 4H, ACH2A), 3.43 (br, 4H, NACH2A), 7.44–7.47 (m,
2H, ArAH), 7.58–7.61 (m, 3H, ArAH), 7.84 (d, J= 8.4 Hz,
1H, ArAH), 8.67 (d, J= 8.1 Hz, 1H, ArAH). 13C NMR
(75 MHz, CDCl3): d (ppm) 46.38, 49.97, 55.17, 121.00,
124.28, 124.54, 125.07, 127.38, 128.46, 130.45, 131.51, 134.35,
135.13, 135.38, 136.63, 141.84, 149.80, 157.37, 194.29 (CO).
HRMS (ESI) m/z calcd for C21H18N3OCl
+ [M]+: 363.1138,
found [M+H]+: 364.1222.l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
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quinolin-11-one (15)
Product 15 was prepared from compound 2 and 1-
ethylpiperazine. The red solid material was isolated in 20%
yield (Rf = 0.43 at CH2Cl2: n-hexane: MeOH= 2:1: 0.5).
Mp 182–184 C (EtOH). FT-IR (KBr; m cm1): 1710 (C‚O).
1H NMR (300 MHz, CDCl3): d (ppm) 1.19 (t, 3H,
J= 7.2 Hz, ACH3), 2.57 (q, 2H, J= 7.4 Hz, ANCH2A),
3.03 (br, 4H, ACH2A), 3.46 (br, 4H, ACH2A), 7.43–7.48 (m,
2H, ArAH), 7.57–7.60 (m, 3H, ArAH), 7.85 (d, J= 8.4 Hz,
1H, ArAH), 8.69 (dd, J= 8.25, 0.9 Hz, 1H, ArAH). 13C
NMR (75 MHz, CDCl3): d (ppm) 12.06, 49.99, 52.69, 52.85,
121.02, 124.30, 124.59, 125.07, 127.36, 128.49, 130.43, 131.53,
134.36, 135.19, 135.38, 136.64, 141.89, 149.84, 15,740, 194.32
(CO). HRMS (ESI) m/z calcd for C22H20N3OCl
+ [M]+:
377.1295, found [M+H]+: 378.1380.
2.3.16. 9-Chloro-6-(4-cyclopentylpiperazin-1-yl)-11H-indeno
[1,2-c]quinolin-11-one (16)
Product 16 was prepared from compound 2 and 1-
cyclopentylpiperazine. The red solid material was isolated in
37% yield (Rf = 0.46 at CH2Cl2: n-hexane: MeOH= 2:1:
0.5). Mp 183–184 oC (EtOH). FT-IR (KBr; m cm1): 1716
(C‚O). 1H NMR (300 MHz, CDCl3): d (ppm) 1.19 (t, 3H,
J= 7.2 Hz, ACH3), 2.57 (q, 2H, J= 7.4 Hz, ANCH2A),
3.03 (br, 4H, ACH2A), 3.46 (br, 4H, ACH2A), 7.43–7.48 (m,
2H, ArAH), 7.57–7.63 (m, 3H, ArAH), 7.85 (d, J= 8.7 Hz,
1H, ArAH), 8.69 (d, J= 8.1 Hz, 1H, ArAH). 13C NMR
(75 MHz, CDCl3): d (ppm) 24.32, 30.67, 50.12, 52.36, 67.87,
120.99, 124.28, 124.61, 125.05, 127.31, 128.50, 130.40, 131.56,
134.36, 135.19, 135.32, 136.58, 141.94, 149.85, 157.48, 194.40
(CO). HRMS (ESI) m/z calcd for C25H24N3OCl
+ [M]+:
417.1608, found [M+H]+: 418.1689.
2.3.17. 9-Chloro-6-(4-(piperidin-1-yl)piperidin-1-yl)-11H-
indeno[1,2-c]quinolin-11-one (17)
Product 17 was prepared from compound 2 and 1-(piperidin-4-
yl)piperidine. The red solid material was isolated in 57% yield.
(Rf = 0.51 at CH2Cl2: n-hexane: MeOH= 2:1: 0.5). Mp 174–
175 C. FT-IR (KBr; m cm1): 1718 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 1.48–1.50 (m, 2H, ACH2A),
1.63–1.65 (m, 2H, ACH2A), 1.72–1.85 (m, 4H, ACH2A),
2.08 (d, J= 11.4 Hz, 2H, ACH2A), 2.38–2.46 (m, 1H, ACH2-
A), 2.60 (s, 4H, ACHA), 2.91–3.02 (m, 2H, ACH2A), 3.76 (d,
J= 12.3 Hz, 2H, ACH2A), 7.41–7.45 (m, 2H, ArAH), 7.55–
7.61 (m, 3H, ArAH), 7.82 (d, J= 8.4 Hz, 1H, ArAH), 8.66
(d, J= 7.8 Hz, 1H, ArAH). 13C NMR (75 MHz, CDCl3): d
(ppm) 24.99, 26.61, 28.77, 50.17, 50.85, 62.51, 120.98, 124.27,
124.42, 124.96, 127.26, 128.36, 130.34, 131.86, 134.37, 135.08,
135.32, 136.45, 141.99, 149.80, 157.82, 194.39 (CO). HRMS
(ESI) m/z calcd for C26H26ClN3O
+ [M]+: 431.1764, found
[M+H]+: 432.1822.
2.3.18. 9-Chloro-6-(4-phenylpiperazin-1-yl)-11H-indeno[1,2-c]
quinolin-11-one (18)
Product 18 was prepared from compound 2 and
1-phenylpiperazine. The red solid material was isolated in
52% yield (Rf = 0.91 at CH2Cl2: n-hexane: MeOH= 3:1:0.5).
Mp 193–194 C (EtOH). FT-IR (KBr; m cm1): 1714 (C‚O).Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (2011H NMR (300 MHz, CDCl3): d (ppm) 3.47 (br, 4H, ACH2A),
3.57 (br, 4H, ACH2A), 6.93 (t, J= 7.2 Hz, 1H, ArAH), 7.04
(d, J= 7.8 Hz, 2H, ArAH), 7.30–7.36 (m, 2H, ArAH), 7.45–
7.51 (m, 2H, ArAH), 7.58–7.70 (m, 3H, ArAH), 7.88 (d,
J= 7.8 Hz, 1H, ArAH), 8.72 (d, J= 8.1 Hz, 1H, ArAH).
13C NMR (75 MHz, CDCl3): d (ppm) 49.44, 50.16, 116.66,
120.53, 121.14, 124.32, 124.52, 125.21, 127.60, 128.49, 129.57,
130.56, 131.60, 134.43, 135.16, 135.49, 136.68, 141.74, 149.78,
151.65, 157.41, 194.30 (CO). HRMS (ESI) m/z calcd for C26-
H20N3OCl
+ [M]+: 425.1295, found [M+H]+: 426.1370.
2.3.19. 6-(4-Benzylpiperazin-1-yl)-9-chloro-11H-indeno[1,2-c]
quinolin-11-one (19)
Product 19 was prepared from compound 2 and 1-
benzylpiperazine. The red solid material was isolated in 41%
yield (Rf = 0.37 at CH2Cl2: n-hexane = 2:1). Mp 178–180 C
(EtOH). FT-IR (KBr; m cm1): 1718 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 2.73 (br, 4H, ACH2A), 3.41 (br,
4H, ACH2A), 3.65 (s, 2H, ACH2A) 7.28–7.47 (m, 7H,
ArAH8,10, ArAH), 7.57–7.63 (m, 3H, ArAH2,3,4), 7.84 (d,
J= 8.7 Hz, 1H, ArAH7), 8.68 (d, J= 7.05 Hz,1H, ArAH1).
13C NMR (75 MHz, CDCl3): d (ppm) 50.11, 53.21, 63.34,
120.97, 124.26, 124.60, 125.04, 127.34, 127.50, 128.42, 128.64,
129.40, 130.42, 131.61, 134.35, 135.11, 135.30, 136.53, 138.46,
141.83, 149.78, 157.55, 194.38 (CO). HRMS (ESI) m/z calcd
for C27H22N3OCl
+ [M]+: 439.1451, found [M+H]+:
440.1503.
2.3.20. 9-Chloro-6-(4-(2-fluorophenyl)piperazin-1-yl)-11H-
indeno[1,2-c]quinolin-11-one (20)
Product 20 was prepared from compound 2 and 1-(2-
fluorophenyl)piperazine. The red solid material was isolated
in 41% yield (Rf = 0.46 at CH2Cl2: n-hexane = 2:1). Mp
182–183 C (EtOH). FT-IR (KBr; m cm1): 1715 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 3.37 (br, 4H, ACH2A),
3.59 (br, 4H, ACH2A), 7.00–7.12 (m, 4H, ArAH), 7.44–7.50
(m, 2H, ArAH), 7.59–7.68 (m, 3H, ArAH), 7.88 (d,
J= 8.1 Hz, 1H, ArAH), 8.71 (d, J= 8.1 Hz, 1H, ArAH).
13C NMR (75 MHz, CDCl3): d (ppm) 50.27, 50.63, 116.47,
116.75, 119.48, 121.09, 123.06, 123.17, 124.31, 124.53, 124.80,
124.86, 125.17, 127.54, 128.49, 130.54, 131.55, 134.40, 135.16,
135.45, 141.76, 149.78, 157.37, 194.29 (CO). HRMS (ESI) m/
z calcd for C26H19ClN3O
+ [M]+: 443.1201, found [M+H]+:
444.1269.
2.3.21. 9-Chloro-6-(4-(2-methoxyphenyl)piperazin-1-yl)-11H-
indeno[1,2-c]quinolin-11-one (21)
Product 21 was prepared from compound 2 and 1-(2-
methoxyphenyl)piperazine. The red solid material was isolated
in 37% yield (Rf = 0.38 at CH2Cl2: n-hexane = 2:1). Mp 129–
131 C (EtOH). FT-IR (KBr; m cm1): 1714 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 3.36 (br, 4H, ACH2A), 3.60 (br,
4H, ACH2A), 3.90 (s, 3H, AOCH3), 6.91–7.07 (m, 4H,
ArAH), 7.47 (t, J= 7.5 Hz, 2H, ArAH), 7.59–7.63 (m, 2H,
ArAH), 7.68 (d, J= 7.8 Hz, 1H, ArAH), 7.87 (d,
J= 8.1 Hz, 1H, ArAH), 8.70 (d, J= 8.4 Hz, 1H, ArAH).
13C NMR (75 MHz, CDCl3): d (ppm) 50.39, 50.75, 55.75,
112.15, 118.68, 121.03, 121.49, 123.55, 124.28, 124.61, 125.09,
127.40, 128.47, 130.46, 131.58, 134.36, 135.15, 135.36, 136.61,l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
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(ESI) m/z calcd for C27H22ClN3O2
+ [M]+: 455.1401, found
[M+H]+: 456.1473.
2.3.22. 9-Chloro-6-(4-(3-methoxyphenyl)piperazin-1-yl)-11H-
indeno[1,2-c]quinolin-11-one (22)
Product 22 was prepared from compound 2 and 1-(3-
methoxyphenyl)piperazine. The red solid material was isolated
in 86% yield (Rf = 0.43 at CH2Cl2: n-hexane = 2:1). Mp 189–
191 C (EtOH). FT-IR (KBr; m cm1): 1723 (C‚O). 1H NMR
(300 MHz, CDCl3): d (ppm) 3.46 (br, 4H, ACH2A), 3.55 (br,
4H, ACH2A), 3.83 (s, 3H, AOCH3), 6.50 (m, J= 8.1 Hz,
1H, ArAH), 6.57 (s, 1H, ArAH), 6.65 (d, J= 8.4 Hz, 1H,
ArAH), 7.22 (d, J= 8.1 Hz, 1H, ArAH), 7.44–7.51 (m, 2H,
ArAH), 7.60–7.68 (m, 3H, ArAH), 7.88 (d, J= 8.1 Hz, 1H,
ArAH), 8.71 (d, J= 7.2 Hz, 1H, ArAH). 13C NMR
(75 MHz, CDCl3): d (ppm) 49.36, 50.08, 55.46, 103.25,
105.29, 109.41, 121.14, 124.31, 124.50, 125.18, 127.60, 128.49,
130.25, 130.56, 131.56, 134.42, 135.15, 135.49, 136.68, 141.70,
149.77, 153.00, 157.35, 161.17, 194.23 (CO). HRMS (ESI) m/
z calcd for C27H22ClN3O2
+ [M]+: 455.1401, found [M+H]+:
456.1464.
2.3.23. 9-Chloro-6-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-
11H-indeno[1,2-c]quinolin-11-one (23)
Product 23 was prepared from compound 2 and 1-(1-methylpi
peridin-4-yl)piperazine. The red solid material was isolated in
31% yield (Rf = 0.90 at CH2Cl2: n-hexane: MeOH= 2:1:
0.5). Mp 208–209 C (EtOH). FT-IR (KBr; m cm1): 1710
(C‚O). 1H NMR (300 MHz, CDCl3): d (ppm) 1.64–1.72 (m,
2H, ACH2A), 1.88 (d, J= 10.5 Hz, 1H, ACH2A), 1.95–2.03
(m, 2H, ACH2A), 2.29 (s, 4H, ACHA, ACH3), 2.82 (br, 4H,
ACH2A), 2.95 (d, J= 9.6 Hz, 1H, ArAH), 3.40 (br, 4H,
ACH2A), 6.47–6.50 (m, 1H, ArAH), 6.57 (s, 1H, ArAH),
6.65 (d, J= 8.4 Hz, 1H, ArAH), 7.22 (d, J= 8.1 Hz, 1H,
ArAH), 7.42–7.47 (m, 2H, ArAH), 7.57–7.61 (m, 3H, ArAH),
7.84 (d, J= 8.4 Hz, 1H, ArAH), 8.68 (d, J= 7.8 Hz, 1H,
ArAH). 13C NMR (75 MHz, CDCl3): d (ppm) 28.54, 46.34,
49.24, 50.49, 55.62, 61.83, 120.96, 124.27, 124.61, 125.04,
127.31, 128.45, 130.40, 131.54, 134.33, 135.15, 135.31, 136.55,
141.89, 149.81, 157.49, 194.38 (CO). HRMS (ESI) m/z calcd
for C26H27ClN4O
+ [M]+: 446.1873, found, [M+H]+:
447.1944.
2.3.24. 9-Chloro-6-(4-(1,4-dioxa-8-azaspiro[4,5]dec-8-yl)-
11H-indeno[1,2-c]quinolin-11-one (24)
Product 24 was prepared from compound 2 and 1,4-dioxa-8-
azaspiro[4,5]dec-8-yl. The red solid material was isolated in
56% yield (Rf = 0.34 at CH2Cl2: n-hexane = 2:1). Mp 218–
219 C (EtOH). FT-IR (KBr; m cm1): 1718 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 1.98 (t, J= 5.7 Hz, 4H,
ACH2A), 3.51 (br, 4H, ANCH2A), 4.04 (s, 4H, AOCH2A),
7.46 (td, J= 8.7, 2.1 Hz, 2H, ArAH), 7.57–7.62 (m, 3H,
ArAH), 7.83 (d, J= 8.7 Hz, 1H, ArAH), 8.69 (dd, J= 8.4,
0.9 Hz, 1H, ArAH). 13C NMR (75 MHz, CDCl3): d (ppm)
35.00, 48.35, 64.66, 107.31, 120.98, 124.25, 125.06, 127.32,
128.41, 130.42, 131.65, 134.38, 135.09, 135.36, 136.57, 141.97,
149.74, 157.34, 194.43 (CO). HRMS (ESI) m/z calcd for C23-
H19ClN2O3
+ [M]+: 406.1084, found [M+H]+: 407.1154.Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
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methanone)-11H-indeno[1,2-c]quinolin-11-one (25)
Product 25 was prepared from compound 2 and (piperazin-1-
yl)(piperidin-1-yl)methanone. The red solid material was iso-
lated in 47% yield (Rf = 0.17 at CH2Cl2: n-hexane = 2:1).
Mp 266–267 C (EtOH). FT-IR (KBr; m cm1): 1647, 1718
(C‚O). 1H NMR (300 MHz, CDCl3): d (ppm) 1.63 (s, 2H,
ACH2A), 3.28–3.47 (m, 16H, ACH2A), 7.42–7.49 (m, 2H,
ArAH), 7.57–7.61 (m, 3H, ArAH), 7.82 (d, J= 8.4 Hz, 1H,
ArAH), 8.69 (d, J= 7.8, 1H, ArAH). 13C NMR (75 MHz,
CDCl3): d (ppm) 24.86, 25.97, 47.12, 47.99, 49.99, 121.16,
124.32, 124.47, 125.20, 127.65, 128.39, 130.58, 131.62, 134.49,
135.09, 135.54, 136.68, 141.56, 149.69, 157.36, 164.84 (CO),
194.20 (CO). HRMS (ESI) m/z calcd for C23H19ClN2O3
+
[M]+: 460.1666, found [M+H]+: 461.1739.
2.3.26. 9-Chloro-6-(4-(3-(piperidin-4-yl)propyl)piperidin-1-
yl)-11H-indeno[1,2-c]quinolin-11-one (26)
Compound 26 was prepared from compound 2 and 4-(3-(piper
idin-4-yl)propyl)piperidine. The pure product was obtained as
red powder (yield 8.4%) (Rf = 0.41 at CH2Cl2: n-
hexane = 2:1). Mp 149–151 C (EtOH). FT-IR (KBr; m
cm1): 1718 (C‚O). 1H NMR (300 MHz, CDCl3): d (ppm)
1.07–1.46 (m, 12H, ACH2A, ACHA), 1.66–1.91 (m, 4H,
ACH2A), 2.54–2.62 (m, 2H, ANCH2(axial)A), 2.90–2.94 (m,
2H, ANCH2(axial)A), 3.06 (d, J= 12 Hz, 2H, ANCH2(equato-
rial)A), 3.70 (d, J= 12.3 Hz, 2H, ANCH2(equatorial)A), 7.41–
7.47 (m, 2H, ArAH), 7.56–7.61 (m, 3H, ArAH), 7.84 (d,
J= 8.4 Hz, 1H, ArAH), 8.68 (d, J= 8.1, 1H, ArAH). 13C
NMR (75 MHz, CDCl3): d (ppm) 23.81, 32.58, 33.95, 35.88,
36.49, 37.04, 37.65, 47.07, 50.75, 120.89, 124.27, 124.44,
124.92, 127.15, 128.31, 130.32, 131.96, 134.33, 135.08, 135.23,
136.43, 142.12, 149.83, 158.22, 194.52 (CO). HRMS (ESI) m/
z calcd for C29H32ClN3O
+ [M]+: 473.2234, found [M
+H]+: 474.2318.
2.3.27. 6-(2-Hydroxyethylthio)-9-chloro-11H-indeno[1,2-c]
quinolin-11-one (27)
Compound 27 was prepared from compound 2 and 2-
mercaptoethanol. The pure product was obtained as red pow-
der (yield 95%) (Rf = 0.23 at CH2Cl2: n-hexane = 2:1). Mp
169–170 C (EtOH). FT-IR (KBr; m cm1): 1718 (C‚O). 1H
NMR (300 MHz, CDCl3): d (ppm) 3.66 (t, J= 5.4 Hz, 2H,
ASCH2A), 4.11 (t, J= 5.25 Hz, 2H, ACH2OH), 4.34 (br,
1H, AOH), 7.47 (dd, J= 8.4, 2.1 Hz, 1H, ArAH), 7.53 (td,
J= 8.4, 1.5 Hz, 1H, ArAH), 7.61 (d, J= 2.1 Hz, 1H, ArAH),
7.65 (td, J= 8.4, 1.5 Hz, 1H, ArAH), 7.87 (d, J= 8.1 Hz, 1H,
ArAH), 7.92 (d, J= 8.1 Hz, 1H, ArAH), 8.72 (d, J= 8.4 Hz,
1H, ArAH). 13C NMR (75 MHz, CDCl3): d (ppm) 34.05,
63.23, 121.54, 124.64, 125.36, 125.83, 127.90, 128.79, 131.14,
134.11, 134.61, 135.02, 136.08, 136.70, 140.76, 149.91, 155.11,
193.79 (CO). HRMS (EI) m/z calcd for C18H12ClNO2S
+[M]+: 341.0277, found 341.0287.
2.3.28. 6-Hydroxy-9-chloro-11H-indeno[1,2-c]quinolin-11-one
(28)
The pure product was obtained as red solid (yield 57%)
(Rf = 0.24 at ethyl acetate: n-hexane = 3:2). Mp 384 C
(dec.). 1H NMR (400 MHz, DMSO-d6): d (ppm) 7.30 (t,l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
6), http://dx.doi.org/10.1016/j.arabjc.2016.06.014
Design, synthesis and biological evaluation of tetracyclic azafluorenone derivatives 9J= 7.6 Hz, 1H, ArAH), 7.40 (d, J= 8.0 Hz, 1H, ArAH), 7.56
(t, J= 7.6 Hz, 1H, ArAH), 7.61 (s, 1H, ArAH), 7.63 (d,
J= 6.8 Hz, 1H, ArAH), 7.93 (d, J= 7.6 Hz, 1H, ArAH),
7.37 (d, J= 8.4 Hz, 1H, ArAH), 12.42 (br, 1H, AOH). 13C
NMR (100 MHz, CDCl3): d (ppm) 115.12, 116.39, 123.91,
124.41, 125.02, 131.62, 133.69, 134.33, 134.82, 135.68, 136.68,
140.78, 141.10, 159.20, 194.44 (C‚O). HRMS (ESI) calcd
for C16H8NO2Cl [M]
+ 281.0244; found [M+H]+ 282.0322,
[MH] 280.0178.
2.3.29. 6-Methoxy-9-chloro-11H-indeno[1,2-c]quinolin-11-one
(29)
The pure product was obtained as orange powder (yield 60%)
(Rf = 0.52 at CH2Cl2: n-hexane = 1:1). Mp 259–261 C
(EtOH). 1H NMR (400 MHz, CDCl3): d (ppm) 4.24 (3H, s,
AOCH3), 7.44 (1H, dd, J= 8.0 Hz, 2.0 Hz, ArAH), 7.47
(1H, td, J= 7.6 Hz, 1.2 Hz, ArAH), 7.59 (1H, d,
J= 2.0 Hz, ArAH), 7.62 (1H, td, J= 8.0 Hz, 1.6 Hz, ArAH),
7.75 (1H, d, J= 7.6 Hz, ArAH), 7.85 (1H, d, J= 8.4 Hz,
ArAH), 8.67 (1H, dd, J= 8.0 Hz, 1.2 Hz, ArAH). 13C
NMR (100 MHz, CDCl3): d (ppm) 53.92, 120.66, 124.09,
124.86, 125.03, 126.68, 127.48, 129.08, 130.25, 134.31, 134.51,
135.16, 136.14, 140.25, 148.79, 158.13, 193.88 (C‚O). HRMS
(ESI) calcd for C17H10NO2Cl [M]
+ 295.0400; found [M+H]+
296.0482.
2.4. Cell culture and MTT assay
All of the synthesized compounds (1–29) were tested against
renal CAKI-1 cell line by MTT assay. Moreover, we selected
four compounds 4, 5, 13, and 26 to evaluate the topo I inhibi-
tory activity. Simultaneously, seventeen of our structures (1, 2,
3, 4, 5, 8, 10, 11, 12, 14, 16, 18, 22, 25, 27, 28 and 29) were
selected by NCI and were investigated against a panel of 60
human tumor cell lines. According to the primary screening,
compounds 1, 5 and 12 were chosen for further cell growthTable 1 Effect of synthetic compounds on cell viability against ren
Compound IC50 (lM)
a ± SDb
CAKI-1 MCF-7
1 >30 >30
2 >30 >30
3 23.26 ± 5.74 3.28 ± 0.88
4 13.52 ± 2.79 3.06 ± 0.77
5 3.85 ± 0.56 2.13 ± 0.57
6 >30 >30
7 >30 >30
8 >30 >30
9 29.64 ± 2.55 >30
10 7.19 ± 0.35 >30
11 9.07 ± 3.86 4.0 ± 0.55
12 1.52 ± 0.21 2.2 ± 0.33
13 1.66 ± 0.11 2.4 ± 0.433
14 8.18 ± 0.69 >30
15 9.66 ± 1.91 3.24 ± 0.66
a IC50 is the concentration of drug (lM) required to inhibit cell growth
b SD: standard derivation, all experiments were independently perform
c CPT (camptothecin) as a reference drug.
d –: not determined.
Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (201inhibition screening for the GI50 (50% growth inhibitory con-
centration), TGI (the total growth inhibition), and LC50 (the
50% lethal concentration) by NCI.
A 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbro
mide (MTT) (Sigma, USA) assay was performed to determine
the cell viability and IC50 values of our synthetic compounds
against the MCF-7 (Mosmann, 1983; Denizot and Lang,
1986) and CAKI-1 cell lines. MCF-7 (3000 cells/well) and
CAKI-1 (5000 cells/well) cells were seeded in 96-well micro-
plates with RPMI-1641 supplemented with 10% FBS and trea-
ted with various concentrations of compounds for 72 h. After
treatment, each well was washed with phosphate-buffered sal-
ine (PBS) three times, 100 lL of the MTT solution (0.5 mg/mL
final concentration in the medium) was added to each well, and
cells were incubated at 37 C for 1 h. MTT is converted to blue
formazan crystals by mitochondrial succinate dehydrogenase.
The plates were then washed with PBS and solubilized in
100 lL of dimethyl sulfoxide (DMSO) per well. The absor-
bances at 540 nm were determined using an enzyme-linked
immunosorbent assay (ELISA) microplate reader. Effects of
our synthetic compounds on cell viability were demonstrated
as the relative activity (relative to the DMSO control group).
2.5. DNA topoisomerase I assay
The topoisomerase I assay kit (TopoGEN, Inc., USA) was
performed as described previously with modifications
(Shchekotikhin et al., 2011). The activity of DNA topoiso-
merase I was determined by evaluating the relaxation of super-
coiled DNA pHOT. The selected synthetic compounds and
camptothecin were dissolved in DMSO at 10 mM as stock
solution. A mixture containing 0.25 lg of the plasmid PHOT
DNA and 1–2 units of recombinant human DNA topoiso-
merase I (TopoGEN INC., USA) was incubated with the pre-
pared 0.5% DMSO (negative control), camptothecin 100 lM
(positive control) or compounds in the buffer (10 mM Tris-
HCl, pH 7.9; 1 mM EDTA; 0.15 M NaCI; 0.1% BSA;al CAKI-1 cells and breast MCF-7 cells.
Compound IC50 (lM) ± SD
CAKI-1 MCF-7
16 19.66 ± 4.75 >30
17 5.83 ± 0.37 3.07 ± 0.36
18 3.59 ± 1.40 3.51 ± 1.4
19 >30 >30
20 10.80 ± 2.91 >30
21 >30 >30
22 12.96 ± 3.16 >30
23 1.81 ± 1.10 2.31 ± 0.35
24 5.95 ± 0.03 >30
25 >30 >30
26 21.83 ± 2.74 >30
27 1.99 ± 0.03 >30
28 >30 >30
29 >30 >30
CPTc –d 1.24 ± 0.72
by 50% of the mean (N= 3).
ed at least three times.
l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
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10 T.-C. Chen et al.0.1 mM Spermidine; 5% glycerol) at 37 C for 45 min. The
reaction was quenched by the addition of sodium dodecyl sul-
fate (final 1% concentration) and proteinase K (final 50 lg/mL
concentration) at 37 C for 15 min. To the reaction mixtures,
the loading buffer containing 0.25% bromophenol blue and
50% glycerol was added 0.1 volume in reactions mixtures.
These samples were electrophoresed on 1% agarose gel at
60 V for 1.5 h with TAE (Tris-acetate-EDTA) as the buffer.
The gels were stained with ethidium bromide for 10 min and
destained with water for 20 min after electrophoresis.N
O
Cl
N
4 (NSC771781)
N
O
Cl
NH
N
5 (NSC772864)
Cl
A
B
Figure 2 Structures and the inhibition of topoisomerase I relaxat
compounds 4, 5, 13, and 26. (B) Effect of compounds 4, 5, 13, and 26
Lane 1: untreated supercoiled pHOT DNA. Lane 2: the pHOT DNA
(compound 4), 5–6 (compound 5), 7–8 (compound 13) and 9–10 (comp
present of drugs at 25 or 100 lM, respectively. Lane 11 is the pHOT DN
Figure 3 Effect of compound 13 on topoisomerase I mediated sup
pHOT DNA. Lanes 2: the pHOT DNA treated with topoisomerase I in
topoisomerase I in the presence of compound 13 at 3.125, 6.25, 12.5 a
Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (2012.6. NCI in vitro 60-cell drug screening experiments
Eight of our synthesized compounds were selected by the NCI,
and their anticancer activities at a single dose of 10 lM were
determined by a sulforhodamine B (SRB) colorimetric assay
according to previous protocols (Sikic, 1991; Monks et al.,
1997; Kandeel et al., 2015). Cells (3000–5000 per well) were
seeded into 96-well microtiter plates for 24 h at 37 C, with
5% CO2, 95% air, and 100% relative humidity. Two plates
of each cell line were fixed with trichloroacetic acid (TCA) asN
O
N
N
H
N
O
Cl
N
HN 2613
ion activities of compounds 4, 5, 13, and 26. (A) Structure of
on topoisomerase I mediated supercoiled pHOT DNA relaxation.
treated with topoisomerase I in the absence of drugs. Lanes 3–4
ound 26) are the pHOT DNA treated with topoisomerase I in the
A treated with topoisomerase I in the presence of CPT at 100 lM.
ercoiled pHOT DNA relaxation. Lanes 1: untreated supercoiled
the absence of drugs. Lanes 3–6 are the pHOT DNA treated with
nd 25 lM.
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Table 2 Cytotoxicity of selected compounds in the NCI in vitro 60-cell drug screen program.
Panel/cell
line
Compounds/growth percenta
Compd.
No.
1 2 3 4 5 8 10 11 12 14 16 18 22 25 27 28 29
NCI No. NSC763972 NSC763969 NSC772856 NSC771781 NSC772864 NSC772860 NSC771782 NSC772857 NSC772862 NSC771783 NSC772859 NSC772861 NSC772863 NSC772858 NSC763971 NSC763970 NSC765596
Leukemia
CCRF-
CEM
22.62 64.86 101.50 92.13 42.00 104.33 88.85 105.04 35.45 92.44 95.17 93.52 93.78 109.87 71.56 105.78 89.25
HL-60
(TB)
3.18 102.00 102.75 95.49 94.33 98.84 97.09 94.50 38.36 101.15 103.04 105.45 99.09 109.78 91.75 102.31 108.77
K-562 12.16 102.16 90.99 88.81 45.29 103.57 89.01 100.89 65.71 92.13 99.26 95.17 94.25 95.70 63.81 97.48 108.53
MOLT-4 43.74 70.83 93.26 88.92 34.63 94.41 88.74 93.29 43.22 92.90 98.39 98.13 95.46 104.77 59.49 95.10 110.33
RPMI-
8226
20.68 92.83 91.82 88.05 81.94 97.99 83.40 95.20 43.57 85.92 94.89 95.33 93.63 104.31 62.28 90.60 90.30
SR 29.86 65.85 91.67 86.12 46.92 98.51 85.94 99.53 55.19 75.13 97.09 95.93 95.05 105.15 61.70 77.02 N.T.
Non-small cell lung cancer
A549/
ATCC
11.94 108.98 96.83 98.85 51.79 101.69 101.47 104.35 18.70 96.43 101.56 90.89 101.22 99.12 76.42 104.88 99.70
EKVX N.T.b 79.27 N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. 30.15 72.14 N.T.
HOP-62 29.61 94.89 87.10 78.02 24.86 64.18 78.71 78.17 61.80 61.42 108.83 N.T. 90.22 96.39 91.46 91.26 96.01
HOP-92 N.T. 71.79 N.T. 44.26 N.T. N.T. 66.08 N.T. N.T. 38.50 N.T. N.T. N.T. N.T. N.T. N.T. 77.75
NCI-
H226
66.09 91.86 92.19 84.79 80.86 94.59 87.21 94.22 49.94 86.17 92.80 79.43 89.19 96.06 80.52 85.66 89.22
NCI-H23 58.72 79.30 86.83 82.62 80.63 90.42 90.40 94.33 49.19 86.27 92.80 83.34 87.22 95.41 66.22 81.56 93.26
NCI-
H322M
89.67 95.38 80.85 78.83 69.83 107.08 91.28 92.29 35.89 87.41 98.50 98.63 91.93 94.59 73.47 90.72 99.80
NCI-
H460
79.73 98.68 84.38 94.17 25.15 101.21 102.14 93.32 66.36 91.83 101.46 97.04 101.76 98.85 79.22 83.32 98.27
NCI-
H522
1.78 89.37 90.50 88.97 77.39 98.45 91.11 92.76 18.08 96.62 98.72 80.10 79.75 99.28 68.89 92.22 95.89
Colon cancer
COLO
205
14.63 99.18 66.47 100.97 45.69 104.79 100.71 96.30 81.49 93.65 104.54 102.19 106.63 98.52 87.39 98.25 108.91
HCC-
2998
88.12 98.52 57.51 81.50 88.65 102.76 107.23 103.16 55.83 103.21 106.04 106.23 105.79 106.23 96.27 102.24 104.46
HCT-116 35.26 105.87 88.31 98.57 36.96 102.51 93.64 89.08 83.19 92.78 91.34 78.18 93.02 101.67 77.94 103.43 88.60
HCT-15 21.44 114.88 66.20 80.49 50.38 97.78 80.29 97.88 78.92 92.83 89.64 80.71 100.39 99.35 80.10 108.54 94.98
HT29 81.42 104.27 99.44 94.89 9.75 104.84 91.34 95.52 80.89 93.76 93.22 82.40 95.93 108.65 84.03 102.38 111.60
KM12 79.30 111.92 66.82 94.44 53.42 94.80 109.99 97.97 47.09 99.06 99.33 98.34 105.95 101.58 84.62 102.73 98.35
SW-620 66.13 98.29 96.25 96.35 43.72 88.89 103.71 91.88 73.67 92.76 93.06 93.14 91.16 92.51 86.99 95.26 98.89
CNS cancer
SF-268 84.54 117.27 97.27 100.26 65.88 96.49 103.58 96.13 34.33 92.35 96.39 85.45 83.89 107.51 96.53 106.64 113.64
SF-295 N.T. 92.80 95.71 93.22 N.T. 96.18 102.43 93.33 23.75 90.01 96.87 60.91 90.05 97.83 73.28 92.48 N.T.
SF-539 104.63 110.08 92.08 87.80 85.04 90.22 96.24 92.93 36.91 95.23 101.34 83.17 83.97 92.98 100.05 105.79 91.49
SNB-19 93.45 101.30 95.95 104.19 94.02 103.87 100.01 113.43 67.25 85.41 95.06 88.40 105.27 108.66 89.19 99.28 96.35
SNB-75 74.33 82.91 79.70 69.12 71.52 84.42 81.55 72.13 22.34 70.00 86.36 33.20 37.76 80.84 66.06 80.33 59.75
U251 20.22 100.63 96.03 98.98 N.T. N.T. 95.72 111.96 N.T. 85.86 N.T. N.T. N.T. 98.15 78.04 96.46 97.67
Melanoma
LOX
IMVI
33.38 84.23 93.40 85.45 N.T. N.T. 91.20 100.04 N.T. 87.17 N.T. N.T. N.T. 103.19 68.41 86.91 116.91
(continued on next page)
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Table 2 (continued)
Panel/cell
line
Compounds/growth percenta
Compd.
No.
1 2 3 4 5 8 10 11 12 14 16 18 22 25 27 28 29
NCI No. NSC763972 NSC763969 NSC772856 NSC771781 NSC772864 NSC772860 NSC771782 NSC772857 NSC772862 NSC771783 NSC772859 NSC772861 NSC772863 NSC772858 NSC763971 NSC763970 NSC765596
MALME-
3M
73.87 102.06. 114.83 111.50 52.55 98.31 136.93 101.05 32.28 106.59 92.48 100.05 92.79 102.62 107.23 103.37 107.54
M14 72.55 109.79 112.68 113.63 76.44 96.60 106.99 101.69 56.24 106.31 105.34 97.52 105.07 101.18 98.89 108.50 96.50
MDA-
MB-435
N.T. 100.46 107.24 97.33 92.72 104.53 106.62 107.70 6.57 98.43 99.93 99.55 100.75 102.57 95.15 100.35 100.31
SK-MEL-
2
110.64 117.11 N.T. 95.09 N.T. N.T. 104.29 N.T. N.T. 104.36 N.T. N.T. N.T. N.T. 95.85 117.12 109.44
SK-MEL-
28
73.75 90.08 114.89 113.43 87.40 105.21 113.81 110.84 91.38 110.81 107.58 104.82 103.93 107.03 86.90 100.02 106.24
SK-MEL-
5
66.21 86.30 80.96 94.89 82.51 98.52 99.19 89.52 59.18 97.67 97.48 99.23 96.87 92.50 68.56 84.87 98.51
UACC-
257
38.15 127.99 107.69 101.11 92.18 106.47 103.31 107.44 39.24 95.34 98.37 98.40 93.79 104.23 106.91 106.31 98.20
UACC-62 86.86 94.45 77.41 78.16 99.56 93.36 88.33 94.90 81.71 96.67 95.06 87.17 86.44 93.92 84.47 95.17 74.08
Ovarian cancer
IGROV1 87.42 92.82 54.41 83.38 43.43 94.36 86.47 72.45 3.23 75.03 85.84 65.13 80.87 81.63 69.73 91.28 96.92
OVCAR-
3
82.98 119.93 84.91 103.48 73.13 97.59 102.34 96.58 22.86 93.41 99.54 98.07 104.27 103.33 89.42 117.80 111.89
OVCAR-
4
40.23 94.13 72.83 84.28 52.50 97.11 96.67 98.19 35.59 94.70 94.20 90.32 87.08 98.31 73.19 80.74 N.T.
OVCAR-
5
104.97 137.00 81.54 89.14 89.34 104.92 90.30 94.37 39.14 99.31 106.41 88.56 98.22 102.33 112.54 126.77 96.81
OVCAR-
8
16.01 101.08 94.33 84.55 61.36 96.38 95.25 96.11 46.09 87.51 96.55 75.82 83.98 104.73 90.21 107.63 98.75
NCI/
ADR-
RES
43.83 96.78 92.22 92.57 69.55 90.28 94.32 102.85 4.00 88.19 100.39 97.88 92.82 107.13 73.58 97.00 94.29
SK-OV-3 N.T. N.T. 92.62 99.12 84.20 99.78 107.26 84.60 57.81 87.98 96.85 78.58 86.02 95.59 N.T. N.T. 119.79
Renal cancer
786-0 103.15 112.40 103.34 108.01 74.13 102.73 103.71 99.53 25.31 89.51 97.90 81.41 81.67 105.05 100.58 114.55 103.51
A498 N.T. N.T. 82.03 96.00 88.98 87.55 93.88 99.15 59.79 72.81 88.64 97.48 104.53 104.44 N.T. N.T. 93.51
ACHN 51.33 111.67 88.46 87.55 55.86 94.75 81.66 86.42 83.29 88.10 100.03 68.58 93.51 95.59 88.12 104.75 90.83
CAKI-1 N.T. 75.67 73.84 84.65 64.35 83.89 94.99 82.68 17.84 83.81 93.83 80.23 86.59 90.50 41.86 71.62 90.65
RXF 393 82.62 112.80 97.15 101.32 51.90 97.51 114.61 106.09 20.51 94.00 95.60 72.95 78.38 107.22 79.39 99.93 114.49
SN12C 48.72 88.03 94.82 95.38 61.60 99.08 96.95 93.10 15.89 83.57 99.08 87.90 88.17 101.12 84.58 96.69 89.48
TK-10 94.62 138.45 65.31 91.84 95.55 134.79 101.98 121.79 47.07 99.56 N.T. 115.61 133.34 131.97 99.82 126.63 N.T.
UO-31 15.98 80.62 56.91 48.63 25.86 76.25 45.74 65.33 40.61 47.60 72.57 65.02 86.64 82.74 56.23 70.50 55.69
Prostate cancer
PC-3 32.02 92.73 89.44 82.55 41.01 90.64 79.64 87.77 58.51 82.93 86.19 79.79 72.83 93.07 58.35 93.44 74.44
DU-145 89.22 113.91 106.88 106.50 65.48 103.47 119.02 106.04 41.83 102.37 110.73 102.96 98.98 114.04 92.27 111.80 121.06
Breast cancer
MCF7 50.00 74.25 5.24 23.99 12.70 64.65 52.31 49.61 100.00 68.30 75.18 53.31 77.46 97.24 67.82 68.09 71.98
MDA- 41.97 87.66 83.87 76.68 25.16 90.96 79.28 93.08 10.45 62.53 82.96 73.80 79.81 93.54 72.56 86.98 74.61
1
2
T
.-C
.
C
h
en
et
a
l.
P
lease
cite
th
is
article
in
p
ress
as:
C
h
en
,
T
.-C
.
et
al.,
D
esign
,
syn
th
esis
an
d
b
io
lo
gical
eva
lu
atio
n
o
f
tetracyclic
azafl
u
o
ren
o
n
e
d
eriv
atives
w
ith
to
p
o
iso
m
erase
I
in
h
i-
b
ito
ry
p
ro
p
erties
as
p
o
ten
tial
an
tican
cer
agen
ts.
A
rab
ian
Jo
u
rn
al
o
f
C
h
em
istry
(2016),
h
ttp
://d
x.d
o
i.o
rg/10.1016/j.arab
jc.201
6.06.014
M
B
-2
3
1
/
A
T
C
C
H
S
5
7
8
T
8
4
.9
8
9
1
.0
1
8
5
.2
8
7
2
.8
4
8
4
.7
0
9
8
.3
8
8
8
.9
3
8
7
.6
8
6
0
.8
8
7
0
.4
7
9
9
.4
0
N
.T
.
7
1
.7
5
1
0
2
.0
6
5
8
.2
8
1
0
5
.9
8
9
2
.7
4
B
T
-5
4
9
9
1
.1
8
1
1
9
.6
2
1
0
1
.8
8
1
0
2
.5
5
8
7
.4
8
9
5
.5
2
9
3
.9
5
9
2
.9
1
5
8
.3
5
8
2
.8
9
1
0
2
.7
4
8
9
.8
3
1
0
1
.5
7
1
0
5
.3
4
9
2
.8
8
1
2
0
.0
8
9
2
.9
5
T
-4
7
D
3
0
.9
8
8
6
.9
7
2
3
.5
3
4
4
.8
8
4
3
.2
8
6
7
.6
8
8
8
.8
1
8
3
.8
6
3
1
.5
4
7
6
.2
7
9
2
.2
0
7
5
.9
3
8
6
.6
8
9
5
.9
9
6
3
.8
9
6
7
.2
3
7
8
.9
7
M
D
A
-
M
B
-4
6
8
4
5
.2
3
1
0
7
.9
2
3
1
.6
1
0
.6
0
3
3
.8
1
9
7
.1
2
5
9
.4
7
9
7
.7
1
3
5
.6
6
9
5
.7
1
1
0
3
.9
9
9
5
.3
7
1
0
1
.0
4
1
0
6
.4
2
7
7
.3
6
8
0
.0
8
9
9
.5
1
M
ea
n
5
5
.9
3
9
8
.1
7
8
4
.1
5
8
7
.1
5
6
2
.4
0
9
6
.2
0
9
3
.6
6
9
4
.7
5
1
4
.3
7
8
8
.1
5
9
6
.5
3
8
7
.2
9
9
2
.1
5
1
0
0
.5
3
7
9
.5
2
9
6
.6
0
9
6
.2
3
D
el
ta
8
6
.9
1
3
3
.3
1
1
1
5
.7
6
8
6
.5
5
5
2
.6
5
3
2
.0
2
4
7
.9
2
4
5
.1
4
8
5
.6
3
4
9
.6
5
2
3
.9
6
5
4
.0
9
5
4
.3
9
1
9
.6
9
4
9
.3
7
2
9
.3
7
4
0
.5
4
R
a
n
g
e
1
4
1
.6
2
7
3
.5
9
1
4
6
.5
0
1
1
3
.0
3
8
9
.8
1
7
0
.6
1
9
1
.1
9
7
2
.1
8
1
6
7
.2
5
7
2
.3
1
3
8
.1
6
8
2
.4
1
9
5
.5
8
5
1
.1
3
8
2
.3
9
5
9
.5
4
6
5
.3
7
a
D
a
ta
o
b
ta
in
ed
fr
o
m
N
C
I
in
vi
tr
o
6
0
-c
el
l
d
ru
g
sc
re
en
p
ro
g
ra
m
a
t
1
0
l
M
.
b
N
.T
.
=
n
o
te
st
.
Design, synthesis and biological evaluation of tetracyclic azafluorenone derivatives 13
Please cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (201a control of the cell population for each cell line at the time of
drug exposure (T0). After additional incubation with the vehi-
cle (DMSO) or the test compounds for 48 h, cells were fixed
with cold 50% (w/v) TCA (final concentration, 10% TCA)
and then incubated for 60 min at 4 C. Plates were then washed
with tap water, and cells were treated with 100 lL of the SRB
solution at 0.4% (w/v) in 1% acetic acid for 10 min at room
temperature. After staining, the plates were washed with 1%
acetic acid to remove any unbound dye, and SRB-bound cells
were solubilized with 0.01 M Trizma base. The absorbance was
measured using a spectrophotometer at a wavelength of
515 nm. Using the absorbance measurements, including time
zero (T0), control growth (C), and test growth in the presence
of a drug (TX), the percentage growth was calculated for each
compound as follows: 100  [(TX  T0)/(C  T0)]  100 for
which concentrations in which TXP T0.
3. Results and discussion
The synthetic methods of 6-substituted 9-chloro-11H-indeno
[1,2-c]quinolin-11-ones are depicted in Scheme 1. The interme-
diate 3-(4-Chlorophenyl)-2-hydroxyquinoline-4-carboxylic
acid (1) was obtained from the reaction of isatin with 4-
chlorophenylacetic acid via the Pfitzinger reaction (Pfitzinger,
1886, 1888). It is a common reaction to provide quinoline-4-
carboxylic acids under basic condition. The following is the
starting material compound 2, 6,9-dichloro-11H-indeno[1,2-c]
quinolin-11-one, and it was produced from intermediate (1)
in POCl3 and carried out in an open system round-bottle flask
with a condenser. The synthetic strategy of compounds 3–26
was accomplished via the reaction of an appropriate amine
with compound 2 in DMF, and then treatment with pyridine
to afford the desired compounds, which were purified by
recrystallization. It was also worthy to note that compound
2 could react with HCl to obtain 28 or with sodium methoxide
(NaOMe) to afford 29, respectively. All the synthetic methods
are illustrated in the procedure Scheme 1.
The effects of the synthesized indenoquinolone derivatives
2–29 on cell viability of the MCF-7 breast cancer cell line
and CAKI-1 renal cancer cell line were experimentally assessed
by performing a MTT assay. Results are summarized in
Table 1 and are expressed as IC50 (lM) values. From the
obtained results, we observed that some indenoquinolones
exhibited interesting activities on the tested cancer cell lines.
We found that the most potent compounds against CAKI-1
cells were 12, 13, 23 and 27 with IC50 values less than 2 lM.
In addition, the potent compounds against MCF-7 cells were
5 (2.13 ± 0.57), 12 (2.20 ± 0.33), 13 (2.40 ± 0.43), and 23
(2.31 ± 0.35) which showed low IC50 values of cell viability.
Of the compounds analyzed, we observed that introduction
of substituted piperazinyl groups at the 6-position of the inde-
noquinolone scaffold could modulate the inhibition of cell via-
bility of MCF-7 and CAKI-1 compared to the
indenoquinolone 2 which possess two chloro atoms. However,
the IC50 values of compounds 14–22 containing a N-
substituted piperazinyl group decreased potency significantly.
Further, the micromolar IC50 values of some potent com-
pounds are presented in Table 1.
According to the antiproliferative activities and the similar
side chains, compounds 4, 5, 13, and 26 were selected to eval-
uate the topoisomerase I inhibition. In Fig. 2, the selected com-l evaluation of tetracyclic azafluorenone derivatives with topoisomerase I inhi-
6), http://dx.doi.org/10.1016/j.arabjc.2016.06.014
Table 3 In vitro anticancer activity by selected compounds 1 (NSC763972), 5 (NSC772864), 12 (NSC772862) in the NCI’s 60 human cancer cell lines.
Panel/cell line (lM) 1 (NSC763972) 5 (NSC772864) 12 (NSC772862)
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50
Subpanel MIDb Selectivity ratio Subpanel MIDb Selectivity ratio Subpanel MIDb Selectivity ratio
Leukemia
CCRF-CEM 1.42 1.114 8.063 15.5 >100 8.24 9.696 1.475 3.50 7.80 6.32 11.000 0.954 >100 >100
HL-60(TB) 1.06 4.28 >100 N.T. N.T. N.T. 36.9 >100 >100
K-562 0.315 >100 >100 8.75 3.61 7.46 7.80 >100 >100
MOLT-4 1.97 15.3 >100 6.24 3.43 7.91 4.41 >100 >100
RPMI-8226 0.549 >100 >100 20.20 4.31 9.73 7.48 >100 >100
SR 1.37 43.4 >100 5.05 4.06 11.60 3.09 >100 >100
Non-small cell lung cancer
A549/ATCC 2.95 5.840 1.538 >100 >100 15.20 11.819 1.210 3.51 6.72 4.87 6.477 1.621 >100 >100
EKVX N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T. N.T.
HOP-62 3.84 >100 >100 4.51 2.83 5.74 12.3 >100 >100
HOP-92 1.21 13.4 >100 3.08 5.80 25.10 N.T. N.T. N.T.
NCI-H226 11.6 >100 >100 1.88 – – 7.77 >100 >100
NCI-H23 3.44 63.6 >100 2.63 4.00 8.35 6.65 >100 >100
NCI-H322M 16 92.3 >100 34.50 13.10 36.20 5.62 >100 >100
NCI-460 7.44 86.3 >100 5.15 3.20 6.74 4.15 >100 >100
NCI-H522 0.238 0.644 3.57 27.60 3.80 7.23 3.98 >100 >100
Colon cancer
COLO 205 3.77 9.560 0.939 15.8 39.8 2.41 18.400 0.778 – – 12.2 9.763 1.075 >100 >100
HCC-2998 11.0 >100 >100 >100 4.08 7.94 30.9 >100 >100
HCT-116 0.807 >100 >100 6.19 3.19 6.06 5.42 >100 >100
HCT-15 0.716 >100 >100 4.37 3.51 7.50 4.34 >100 >100
HT29 39.0 >100 >100 4.23 3.16 6.28 7.84 >100 >100
KM12 4.62 >100 >100 6.48 3.11 5.96 2.50 >100 >100
SW-620 7.01 >100 >100 5.12 3.06 6.67 5.14 >100 >100
CNS cancer
SF-268 4.28 14.364 0.625 >100 >100 17.70 14.875 0.962 3.27 6.52 8.71 8.053 1.304 >100 >100
SF-295 10.8 87.9 >100 17.80 4.60 9.85 7.79 >100 >100
SF-539 23.1 64.2 >100 20.90 3.15 5.86 14.2 >100 >100
SNB-19 30.9 >100 >100 18.20 3.42 – 8.27 >100 >100
SNB-75 N.T. N.T. >100 3.25 2.35 4.86 4.53 >100 >100
U251 2.74 >100 >100 11.40 3.06 5.88 4.82 >100 >100
Melanoma
LOX IMV1 0.64 10.637 0.844 57.00 >100 6.04 15.654 0.914 3.04 6.02 4.74 19.894 0.528 >100 >100
MALME-3M 8.32 42.20 >100 17.30 3.83 7.46 8.87 >100 >100
M14 3.75 >100 >100 16.50 5.48 19.30 7.49 >100 >100
MDA-MB-435 3.97 >100 >100 20.20 3.86 7.62 7.01 >100 >100
SK-MEL-2 17.10 50.20 >100 37.70 4.73 10.40 7.36 >100 >100
SK-MEL-28 33.00 >100 >100 6.00 3.21 5.83 >100 >100 >100
SK-MEL-5 7.36 22.50 56.5 1.15 2.61 – 4.10 >100 >100
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UACC-257 6.39 65.10 >100 21.20 3.39 6.37 35.1 >100 >100
UACC-62 15.20 88.40 >100 14.80 3.31 6.68 4.38 >100 >100
Ovarian cancer
IGROV1 14.3 13.649 0.658 >100 >100 11.20 17.448 0.820 3.62 7.82 5.94 13.591 0.772 >100 >100
OVCAR-3 4.46 95.1 >100 N.T. N.T. N.T. 12.8 >100 >100
OVCAR-4 8.83 21.9 49.30 2.99 2.79 5.68 6.39 >100 >100
OVCAR-5 16.1 66.1 >100 21.50 3.32 6.52 34.5 >100 >100
OVCAR-8 1.49 >100 >100 13.80 3.63 7.76 8.66 >100 >100
NCI/ADR-RES 2.26 25.2 >100 19.30 3.67 7.41 22.5 >100 >100
SK-OV-3 48.1 >100 >100 35.90 5.57 17.20 4.35 >100 >100
Renal cancer
786-O 23.4 10.988 0.817 >100 >100 26.80 12.733 1.124 3.29 6.01 23.5 6.370 1.648 >100 >100
A498 6.75 71.7 >100 8.76 1.78 50.80 2.63 >100 >100
ACHN 4.2 >100 >100 6.44 3.04 5.89 3.14 >100 >100
CAKI-1 7.92 >100 >100 14.80 3.26 6.80 2.52 >100 >100
RXF 393 17.9 63.6 >100 N.T. N.T. N.T. 4.55 >100 >100
SN12C 3.24 >100 >100 4.12 2.87 6.16 5.42 >100 >100
TK-10 22.7 68.9 >100 24.60 3.70 6.38 N.T. N.T. N.T.
UO-31 1.79 35.3 >100 3.61 2.88 6.48 2.83 >100 >100
Prostate cancer
PC-3 0.606 2.968 3.026 >100 >100 12.50 15.650 0.914 3.82 8.98 5.93 5.360 1.959 >100 >100
DU-145 5.33 >100 >100 18.80 2.94 5.43 4.79 >100 >100
Breast cancer
MCF7 7.73 7.280 1.234 >100 >100 0.44 12.345 1.159 2.60 5.54 5.42 6.813 1.541 >100 >100
MDA-MB-231/ATCC 2.44 13.8 75.1 2.32 2.71 5.70 7.23 >100 >100
HS 578T 20.3 >100 >100 19.30 10.00 46.10 4.77 >100 >100
BT-549 7.55 >100 >100 32.50 9.50 45.50 10.6 >100 >100
T-47D 0.84 2.86 8.96 17.80 3.56 7.19 8.44 >100 >100
MDA-MB-468 4.82 29.4 >100 1.71 3.07 – 4.42 >100 >100
MIDa 8.982 14.306 10.498
MIDa = Average sensitivity of all cell lines in lM.
MIDb = Average sensitivity of all cell lines of a particular subpanel in lM.
Selectivity ratio =MIDa:MIDb.
N.T. = no test.
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16 T.-C. Chen et al.pounds showed various inhibitory effects against topoiso-
merase I at 25 and 100 lM. Among them, the synthetic com-
pound 13 not only exhibited more potent inhibitory activity
than compounds 4, 5, 26, and CPT, but also completely
blocked topoisomerase I-mediated DNA relaxation at
25 lM. Compound 7 was chosen for further testing against
topoisomerase I in a concentration-dependent manner doses
at 3.125, 6.25, 12.5, and 25 lM (Fig. 3).
The effects of sixteen compounds 1 (NSC763972), 2
(NSC763969), 3 (NSC772856), 4 (NSC771781), 5
(NSC772864), 8 (NSC772860), 10 (NSC771782), 12
(NSC772862), 14 (NSC771783), 16 (NSC772859), 18
(NSC772861), 22 (NSC772863), 25 (NSC772858), 27
(NSC763971), 28 (NSC763970), and 29 (NSC765596) on cell
viability were evaluated against the NCI-60 human tumor cell
lines at 10 lM in vitro using the SRB protein-binding dye
(Sikic, 1991; Monks et al., 1997). As shown in Table 2, this
class of compounds bearing ethanolthiol group (27), hydroxyl
group (28), methoxy group (29), and several N-substituted
piperazinyl groups revealed no significant activities for all
the cancer cell lines which respond to the previous in vitro con-
sequences. Three synthetic compounds 1, 5, and 12 were
selected for an advanced 60-cell panel assay at five logarithm
concentrations (102, 101, 100, 101 and 102 lM) and the
results were indicated with GI50, TGI and LC50, because of
their significant cytotoxicity when tested using MTT viability
assay.
Compound 1, the average concentration required to inhibit
GI50 was 8.982 lM with a range of 0.238 lM (non-small cell
lung cancer: NCI-H522) to >39.0 lM (colon cancer: HT-
29). With 5, the average concentration required to inhibit
GI50 was 14.36 lM with a range of 0.44 lM (breast cancer:
MCF-7) to >100 lM (colon cancer: HCC-2998). Further-
more, the average GI50 concentration of 12 was 10.498 lM,
with a range of 2.52 lM (ovarian cancer: IGROV1) to
>100 lM (melanoma: SK-MEL-28). Compounds 1, 5, and
12 exhibited dose-dependent inhibition of proliferation in all
60 cancer cell lines. Compound 1 is active against most of
the cancer cell lines with GI50 values <1 lM for 12% (7/58)
of the cell lines. With initial assessment at relative doses, 12
is more potent than 5. Compound 12 exhibited highly inhibi-
tory effect against most of the cancer cell lines with GI50 values
<5 mM for 36.8% of the 57 cell lines. The GI50, TGI and
LC50 values of the active compounds within each series are
given in Table 3.
4. Conclusion
Because of the anticancer potential demonstrated by the indeno-
quinolone scaffold, an approach for synthesizing 6-substituted-9-chlo
ro-indenoquinolones was developed, and the inhibition activities of
the synthetic compounds on cell viability were evaluated. Based on
our biological results, it was envisioned that introduction of piper-
azinyl groups with a 4-substituted side chain at the 6-position of the
indenoquinolone scaffold decreased the cell viability of the breast can-
cer cell line MCF-7 and renal cancer cell line CAKI-1. Among the syn-
thesized compounds, 12 (with a piperazinyl group) and 13 (with a 2-
methylpiperazinyl group) were the most-active compound exhibiting
potent inhibitory activity on the cell viability of MCF-7 and CAKI-1
cells. Through a series of promising in vitro experiments, we found that
6-substituted-9-chloro-indenoquinolone derivatives, especially com-
pound 13, not only exhibited preferential growth inhibition effects
toward cancer cell lines but also showed the inhibitory effect onPlease cite this article in press as: Chen, T.-C. et al., Design, synthesis and biologica
bitory properties as potential anticancer agents. Arabian Journal of Chemistry (201topoisomerase I. Based on our results and structure–activity relation-
ships (SARs) studies, compounds 12 and 13 could be potent antibreast
cancer candidates and promising lead compounds that warrants fur-
ther structure optimization.
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